EUPATI has chosen to use the term medicines development throughout its texts.
EUPATI has chosen to use the term medicines development throughout its texts.Tags: Nyu Creative Writing Masters5 Page Research PaperEssay On Man Epistle 1Proposal ResearchExpository Essay Writing PromptsContemporary Printmaking EssayExample Of Experimental Research PaperMla Essay TipsLean Canvas Business Plan
Figure 2 shows the elements that make up the Common Technical Document (CTD), the dossier that is submitted to the regulatory authorities as a Marketing Authorisation Application (MAA) in Canada, Europe, Japan, Switzerland, the United States, and others.
The format of the CTD has been developed by the International Council for Harmonisation [ICH] The International Council on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) produces harmonised guidelines for global pharmaceutical development, and their regulation.
Regulatory Affairs (RA) departments are (or should be) an integral part of all steps throughout the life-cycle of the medicinal product.
Regulatory Affairs are responsible in particular for the applications that must be submitted before every Clinical trial A clinical trial is a clinical study in which participants are assigned according to a pre-defined therapeutic strategy or plan (protocol) to receive a health-related intervention, such as a medicine, in order to investigate its effects on health outcomes, usually compared to another (or sometimes no) treatment.
Previously, the terms clinical study and clinical trial were used synonymously. In order to market a medicine, a submission (an application) must be made to the relevant regulatory authority, for example the European Medicines Agency (EMA).
Submissions provide comprehensive information about the medicine, its formulation, the trials it has undergone, its intended use, and its risks and benefits.submission of the dossier for the Marketing Authorisation Application (MAA), and other activities after the MA is granted, for instance applying for a change to the marketing authorisation (a variation).
A single application is submitted to the EMA for evaluation by the Agency’s Scientific committees.
If the assessment is positive, a single marketing authorisation is issued by the European Commission.
Figure 1 illustrates the development process for a new, innovative medicine.
This kind of medicine would require a full dossier to be submitted, in which all elements of documentation for the medicine must be included.